PMID- 17218562
OWN - NLM
STAT- MEDLINE
DCOM- 20071105
LR  - 20151119
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 131
IP  - 1
DP  - 2007 Jan
TI  - Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary 
      arterial hypertension.
PG  - 101-8
AB  - BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare condition 
      characterized by elevated pulmonary artery pressure leading to right-heart 
      failure and death. Endothelin (ET)-1 has been shown to play a significant 
      pathogenic role in PAH. ET-3 has not yet been investigated in PAH. METHODS: ET-1 
      and ET-3 plasma concentrations were measured in 33 PAH patients prior to any 
      specific PAH therapy and in 9 control subjects. In PAH patients, hemodynamic 
      parameters measured by right-heart catheterization, 6-min walk distance (6MWD), 
      New York Heart Association (NYHA) functional class, and time until lung 
      transplantation or death were recorded. RESULTS: In patients with PAH, levels of 
      ET-1 were increased while those of ET-3 were decreased, as compared to control 
      subjects (p < 0.005 for both comparisons). ET-1/ET-3 ratio varied little in 
      control subjects, while it increased threefold in PAH patients (p < 0.0001). ET-1 
      correlated positively with right atrial pressure (RAP), indexed total pulmonary 
      resistance, and negatively with cardiac index and venous saturation of oxygen 
      (Svo(2)). ET-3 correlated positively with 6MWD. ET-1/ET-3 ratio correlated 
      positively with RAP, negatively with Svo(2) and 6MWD, and was also associated 
      with NYHA functional class. ET-1/ET-3 ratio was associated with prognosis in this 
      sample of PAH patients treated with specific therapies. CONCLUSIONS: PAH is 
      characterized by elevated ET-1 and ET-1/ET-3 ratio and decreased ET-3 plasma 
      concentrations. All of them correlate with hemodynamic and clinical markers of 
      disease severity. ET-1/ET-3 ratio might be a novel prognostic factor in PAH. 
      These preliminary data should be validated in a large prospective multicenter 
      cohort of PAH patients.
FAU - Montani, David
AU  - Montani D
AD  - Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, Service de 
      Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance 
      Publique-Hopitaux de Paris, Universite Paris-Sud. 157 rue de la Porte de Trivaux, 
      92140 Clamart, France.
FAU - Souza, Rogerio
AU  - Souza R
FAU - Binkert, Christoph
AU  - Binkert C
FAU - Fischli, Walter
AU  - Fischli W
FAU - Simonneau, Gerald
AU  - Simonneau G
FAU - Clozel, Martine
AU  - Clozel M
FAU - Humbert, Marc
AU  - Humbert M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Biomarkers)
RN  - 0 (Endothelin-1)
RN  - 0 (Endothelin-3)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Endothelin-1/*blood
MH  - Endothelin-3/*blood
MH  - Female
MH  - Humans
MH  - Hypertension, Pulmonary/*blood/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Statistics, Nonparametric
EDAT- 2007/01/16 09:00
MHDA- 2007/11/06 09:00
CRDT- 2007/01/16 09:00
PHST- 2007/01/16 09:00 [pubmed]
PHST- 2007/11/06 09:00 [medline]
PHST- 2007/01/16 09:00 [entrez]
AID - S0012-3692(15)49886-1 [pii]
AID - 10.1378/chest.06-0682 [doi]
PST - ppublish
SO  - Chest. 2007 Jan;131(1):101-8. doi: 10.1378/chest.06-0682.